Navigation Links
Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
Date:6/17/2009

OSLO, Norway, June 17 /PRNewswire-FirstCall/ --

- New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments

Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.

    Key results compared to published clinical data:

    - Median survival three times longer (5.5 months vs. 1.5 months)
    - Remission rate significantly increased (15% vs 2.5%, p<0.0001)
    - Well tolerated - short-term mortality substantially lower (13 per
      cent vs. 25 per cent)

Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid leukaemia (AML) patients who have failed two previous therapeutic regimens. There is currently no standard therapy available for these patients and life expectancy is very short. It is in this patient group that Clavis Pharma has evaluated the safety and efficacy of elacytarabine.

Extended survival, improved remissions

In the Phase II study, 61 patients with late stage AML who failed to respond or relapsed after two separate rounds of treatments received third-line therapy (also called second salvage) with intravenous elacytarabine. The response to treatment was compared with a detailed historical outcome analysis of 594 similar second salvage AML patients, who were treated at the MD Anderson C
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... patient monitors and sensors, reported a net loss of $245,000 ... $6 million. , ,Sales were down from nearly $6.6 million ... also down, and the firm's net loss came down from ... at about $3.7 million. , ,Criticare (AMEX:CMD) said that several ...
... Now that spring is in gear, women looking for new ... a "shorts and tee shirts" alternative to the traditional conference ... until Sunday, with yoga in the mornings and two full ... of summer camp. ... Your physical surroundings and the things ...
... the Alzheimer's disease drug market in the United ... percent annually for the next five years. , ... Markets for Alzheimer's Disease Medications 2005," include Pfizer, ... Alzheimer's drug market that generated more than $1.3 ...
Cached Biology Technology:Women in technology confab comes to Wisconsin 2Alzheimer's drug market to hit $5.5 billion by 2009, study says 2
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... at the University of Liverpool has found how worms ... with the body. , Dr Paolo Paoletti, alongside his ... mathematical model for earthworms and insect larvae which challenges ... get around. , The most widely accepted model is ... that the central brain of these creatures generates rhythmic ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Secrets of how worms wriggle uncovered 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... Scientists who have determined how much carbon is stored ... be used to accelerate global discussion about the strategy ... In an era of competing land use demands, the ... are abundant sources of other ecological goods and services ...
... College of Clinical Pharmacology (ACCP) has awarded ... director of Pediatric Clinical Pharmacology at Children,s National ... Dr. van den Anker, a neonatologist by training, ... contributions to pediatric clinical pharmacology," according to the ...
... 8, 2008-- The McClellan Nuclear Radiation Center (MNRC) in ... to detect corrosion and defects in aircraft structure using ... currently helping soil scientists understand the function of plant ... Scientists at the University of California in Davis present ...
Cached Biology News:Scientists point to forests for carbon storage solutions 2Scientists point to forests for carbon storage solutions 3Scientists point to forests for carbon storage solutions 4Scientists point to forests for carbon storage solutions 5US Air Force technology helps scientists understand plant root function 2
...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: